Patents
Literature
56 results about "Amyloid beta" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Amyloid beta (Aβ or Abeta) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of the amyloid plaques found in the brains of people with Alzheimer's disease. The peptides derive from the amyloid precursor protein (APP), which is cleaved by beta secretase and gamma secretase to yield Aβ. Aβ molecules can aggregate to form flexible soluble oligomers which may exist in several forms. It is now believed that certain misfolded oligomers (known as "seeds") can induce other Aβ molecules to also take the misfolded oligomeric form, leading to a chain reaction akin to a prion infection. The oligomers are toxic to nerve cells. The other protein implicated in Alzheimer's disease, tau protein, also forms such prion-like misfolded oligomers, and there is some evidence that misfolded Aβ can induce tau to misfold.
Extracellular vesicle drug delivery system, preparation method thereof and application of extracellular vesicle drug delivery system in treatment of Alzheimer's disease
PendingCN121825870AOrganic active ingredientsCell dissociation methodsAmyloid betaMicroglial cell activation
The invention belongs to the technical field of biological medicine, and particularly relates to an extracellular vesicle drug delivery system, a preparation method thereof and application of the extracellular vesicle drug delivery system in treatment of Alzheimer's disease. According to the invention, one or more of stilbene glucoside, emodin, kaempferol, resveratrol and quercetin are used for regulating and controlling the expression of miRNA (micro Ribonucleic Acid) related to the disease progress in the extracellular vesicles, and the result shows that one or more of miR-let-7c-5p, miR-486-5p, miR-132-3p, miR-160b and miR-129-5p is remarkably up-regulated, and one or more of miR-342-3p, miR-16-5p and miR-125b-5p is remarkably down-regulated. The regulated extracellular vesicles can be used for treating Alzheimer's disease, relieving Tau protein abnormal phosphorylation, reducing amyloid protein beta deposition, inhibiting microglial cell activation, protecting neuronal cells and relieving memory deficits.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Monoclonal antibody against amyloid beta, and method for measuring amyloid beta-related peptide using said antibody
ActiveUS12650435B2Immunoglobulins against animals/humansPeptide preparation methodsMicroorganismAmyloid beta
The present invention provides a novel anti-Aβ antibody capable of detecting an Aβ related peptide, a method for measuring an Aβ related peptide in a biological sample by immunochemically using the above-mentioned novel anti-Aβ antibody, and a kit. A monoclonal antibody that recognizes an Aβ related peptide, and is produced by a hybridoma deposited under the accession number NITE BP-02998 at the NITE Patent Microorganisms Depositary of the National Institute of Technology and Evaluation. An antibody-immobilized carrier that includes a carrier and the monoclonal antibody defined in claim 1 bound to the carrier. A kit for measuring an Aβ related peptide, comprising the antibody-immobilized carrier.
Owner:SHIMADZU CORP
Compounds, systems, and techniques for removal of peripheral amyloid beta peptide with albumin binding competitors
Compounds, systems, kits, methods, and / or apparatuses may be operative to reduce amyloid beta (Aβ) peptide in a patient, including a central nervous system (CNS) of the patient and / or a periphery (non-CNS portion) of the patient. In some embodiments, a displacer fluid comprising a Aβ displacer may be introduced to the patient to bind to a blood protein, such as albumin, that binds Aβ (for instance, Aβ peptide or non-plaque Aβ) in the patient periphery. Binding of the displacer to the blood protein may facilitate more free Aβ peptide (for instance, Aβ monomers) in the periphery for clearance via natural processes, such as through the liver or kidneys, and / or artificial processes, such as dialysis. Increased removal of the free Aβ peptide in the periphery may ultimately lead to less Aβ peptide in the CNS, which may decrease Aβ plaque formation in Alzheimer's Disease (AD) patients. Other embodiments are described.
Owner:FRESENIUS MEDICAL CARE HOLDINGS INC
Use of methylated peptide as therapeutic agent for degenerative brain diseases
The present invention relates to a use of a methylated peptide as a therapeutic agent for degenerative brain diseases. Specifically, it has been confirmed that the methylated peptide according to the present invention exhibits improved solubility, bioavailability, phagocytosis by microglia, and anti-inflammatory efficacy compared to a conventional unmodified peptide, and exhibits excellent amyloid beta reduction efficacy compared to a conventional unmodified peptide in an animal model of degenerative brain diseases. Therefore, the methylated peptide according to the present invention can be usefully used as an active ingredient of a composition for preventing or treating degenerative brain diseases and cognitive impairment, learning disability, or memory impairment associated therewith.
Owner:KINE SCI CO LTD
Anti-n3pglu amyloid beta antibodies and uses thereof
PCT designated stageWO2025228316A1Nervous disorderImmunoglobulins against animals/humansAntiendomysial antibodiesAmyloid beta
Provided herein are antibodies that selectively bind N3pGlu Amyloid Beta peptide and their use in treating conditions or diseases characterized by deposition of Amyloid Beta.
Owner:JACOBIO PHARMACEUTICALS CO LTD
Novel molecule for diagnosis
To provide a novel amyloid beta (A beta) binding molecule, especially an amyloid beta antibody or an antigen-binding fragment thereof, and / or use of them.SOLUTION: There is provided an amyloid beta binding antibody including: VH-CDR1 including a specific amino acid sequence, VH-CDR2 including a specific amino acid sequence, VH-CDR3 including a specific amino acid sequence, VL-CDR1 including a specific amino acid sequence, VL-CDR2 including a specific amino acid sequence, and VL-CDR3 including a specific amino acid sequence; or an antigen-binding fragment thereof. In one embodiment, independently of an amyloid beta peptide or a three-dimensional structure states of a seed, an amyloid beta binding antibody or an antigen binding fragment thereof selectively binds to an amyloid beta peptide or seed in a solution, or captures the amyloid beta peptide or seed.SELECTED DRAWING: None
Owner:AC IMMUNE SA
Catalytic antibodies and methods of use thereof
PendingCN121248772AImmunoglobulins against animals/humansDisease diagnosisAntiendomysial antibodiesAmyloid beta
The present application provides methods, compositions and kits for determining SHD-catalyzed antibody levels in a biological sample and for treating or preventing protein aggregation disease (PAD) in an individual. Catalytic antibodies that specifically recognize amyloid beta (A beta) peptides and methods of using the same are also provided.
Owner:AB STUDIO INC
Composition for predicting clinical stage of alzheimer's disease and kit using the same
ActiveUS12578347B2Microbiological testing/measurementDisease diagnosisRyanodine receptorAmyloid beta
The composition for predicting Alzheimer's disease prognosis comprising a detection reagent that specifically binds to any one or more genes selected from the group consisting of Nos1 (Nitric oxide synthase 1), Aph1B (Anterior pharynx defective 1 homolog B), Ryr3 (Ryanodine receptor 3), Atf6 (Activating transcriptional factor 6), Ip3r (Inositol trisphosphate receptor), Nep (Neprilysin), Cdk5 (cyclin dependent kinase 5) and Abad (Amyloid beta-binding alcohol dehydrogenase), a kit, and a method for providing information on Alzheimer's disease prognosis of the present invention can rapidly and accurately predict the prognosis of Alzheimer's disease, and can determine the prognosis for a drug by comparing the expression level before and after drug administration, so that an appropriate treatment direction can be determined according to the predicted prognosis. Therefore, they have an effect that can greatly contribute to the reduction of mortality due to Alzheimer's disease.
Owner:INDUSTRYACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
A combination of scyllo-inositol and n-acetyl cysteine and related compounds
PCT designated stageWO2025254861A1Nervous disorderHydroxy compound active ingredientsPhysiologyAmyloid beta
The invention relates to the use of scyllo-inositol alone or in combination with other active ingredients including the compound N-acetylcysteine or a derivative thereof to support cognitive health in a subject that takes the product or combination product. The compositions, which are inclusive of oral dosage forms such as tablets or capsules, are provided to the subject which is inclusive of humans or other mammals such as dogs or cats or other animals in need of cognitive improvement. The combination product(s) break up amyloid beta aggregates and promote the clearance of amyloid beta fibrils from the glymphatic system as well as the treatment of disease and conditions that are acerbated by free radicals.
Owner:EIRGEN PHARMA LTD
Intracellular domain of AXL or fragment derived therefrom, and use for regulating autophagy using same
PCT designated stageWO2025264067A1Polypeptide with localisation/targeting motifCompound screeningIntracellularAmyloid beta
The present invention relates to an intracellular domain of AXL or a fragment derived therefrom, and a use for regulating autophagy using same, wherein the intracellular domain of AXL or the fragment derived therefrom can regulate a selective autophagy pathway in response to an intracellular amyloid beta signal.
Owner:INST FOR BASIC SCI
Animal model for rapid attack of Alzheimer's disease amyloid beta plaque lesion
Provided herein are compositions comprising a nucleic acid encoding an amyloid-beta precursor protein and / or a nucleic acid encoding premature protein-1, cells comprising these compositions, animals comprising these compositions, methods of making these cells and animals, methods of modeling Alzheimer's disease, and methods of preparing such cells and animals. A method of assessing a treatment candidate for treating or ameliorating a symptom or phenotype of Alzheimer's disease, and a method of assessing a treatment candidate for preventing or preventing a symptom or phenotype of Alzheimer's disease.
Owner:REGENERON PHARMACEUTICALS INC
Methods of delaying or preventing the onset of alzheimer's disease using crenezumab
PendingUS20250361292A1Nervous disorderImmunoglobulins against animals/humansAntiendomysial antibodiesAmyloid beta
Provide herein are methods of treating human patients with familial Alzheimer's disease that result in delayed in symptom onset and / or slowed cognitive decline by administering a humanized monoclonal anti-amyloid beta (Aβ) antibody.
Owner:GENENTECH INC +1
Bispecific binding molecule
The present disclosure provides a bispecific binding molecule, which binds to AβpE3, i.e. to an N-terminally truncated and pyroglutamate-modified form of amyloid beta (Aβ), and to the protease-like domain of human transferrin receptor 1 (hTfR1), as well as therapeutic and diagnostic uses thereof.
Owner:BIOARCTIC AB
Neutralizing anti-amyloid beta antibodies for the treatment of Alzheimer's disease
Binding polypeptides (e.g., antibodies and antigen-binding fragments thereof) that specifically bind one or more species of soluble, AD brain-derived synaptotoxic amyloid beta (Aβ) without binding to classical monomeric, protofibrillar or fibrillar Aβ, are provided. Pharmaceutical compositions comprising binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of making binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of treating Alzheimer's disease using binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of reducing one or more symptoms of Alzheimer's disease using binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided.
Owner:SANOFI SA(FR) +1
Method for diagnosing early and classifying stages of alzheimer's disease and determining amyloid beta accumulation in brain by using tau protein-derived phosphorylated peptide
A method for early diagnosis or stage classification of Alzheimer's disease includes obtaining a tau protein-derived phosphorylated peptide from an isolated biological sample and quantifying the tau protein-derived phosphorylated peptide. Through the quantification of tau protein-derived phosphorylated peptides, it is possible to effectively diagnose Alzheimer's disease at an early stage or classify its stages, and determine the accumulation of amyloid beta in the brain.
Owner:GWANGJU INST OF SCI & TECH +2
Bispecific antibodies targeting amyloid beta and human CD98HC and methods of uses
Owner:SIRONAX SWITZERLAND GMBH +1
Anti-amyloid beta antibodies and uses thereof
The present application provides anti-Aβ constructs (e.g., anti-Aβ antibodies) that bind to Aβ (e.g., Aβ40 and Aβ42), nucleic acid molecules encoding an amino acid sequence of the anti-Aβ constructs, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-Aβ constructs, pharmaceutical compositions containing the anti-Aβ constructs, and methods of using the anti-Aβ constructs or compositions.
Owner:DYNAMICURE BIOTECHNOLOGY LLC
Bispecific binding molecule
PCT designated stageWO2026068532A1Nervous disorderAntibody ingredientsAmyloid betaTransferrin receptor
The present disclosure provides a bispecific binding molecule, which binds to protofibrils of amyloid beta and to the protease-like domain of human transferrin receptor 1 (hTfR1), as well as therapeutic and diagnostic uses thereof.
Owner:BIOARCTIC AB
Polynucleotides encoding APOA-1 fusion polypeptides
Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin / kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.
Owner:THERIPION INC
In vitro diagnostic method of neurodegenerative disease
The present invention relates to a method for the in vitro diagnosis of a neurodegenerative disease in a human or animal individual in the early stage, comprising a step comprising the detection of the presence of at least one marker selected from the group consisting of derived forms of amyloid beta (A beta) peptides, the derivative forms are selected from oligomers of the peptide and pre-fibrotic and fibrotic aggregated forms of the peptide, and derivative forms of a phosphorylated tau protein, and the derivative forms are selected from over-phosphorylated forms of the protein, aggregated forms of the protein and modified phosphorylated tau proteins resulting from one or more post-translational modifications; the presence of a marker is detected in a fecal sample of the individual.
Owner:UNIVERSITE GRENOBLE ALPES +1
Anti-amyloid beta fibril / oligomer antibodies and uses thereof
The present disclosure provides anti-amyloid beta (Aβ) antibodies and antibody fragments that preferentially bind to soluble amyloid Aβ fibrils / oligomers and trigger ADPCs in microglia; anti-amyloid beta (Aβ) antibodies and antibody fragments that reduce soluble amyloid Aβ fibril / oligomer levels and insoluble amyloid Aβ plaques in brain tissue; and uses of anti-Aβ fibril / oligomer antibodies and antibody fragments in the treatment, prevention, diagnosis, screening and monitoring of conditions associated with Aβ protein aggregation, in particular Alzheimer's disease (AD).
Owner:MABWELL THERAPEUTICS INC
Methods of treating alzheimer's disease
PCT designated stageWO2026064441A1Nervous disorderImmunoglobulins against animals/humansImmuno assayAmyloid beta
The disclosure is related to methods of treating a subject with Alzheimer's Disease (AD) using anti-amyloid beta (Aβ) therapy. The patient may be treated based on the measurement and analysis of biomarker levels, such as plasma Aβ42 / 40 ratio, pTau181 and pTau217. The disclosure includes a systematic approach called CP Convert for converting biomarker measurements across different analytical platforms, enabling comparison of pTau217 data from LC-MS / MS, SIMOA, and chemiluminescent enzyme immunoassay platforms. Methods demonstrate that pTau217 has superior diagnostic accuracy compared to Aβ42 / 40 ratio and pTau181 for detecting brain amyloid positivity. Implementation of pTau217 prescreening can significantly reduce Aβ-PET testing, decreasing patient burden and clinical trial costs. The CP Convert methodology can be validated using independent cohorts, demonstrating robust cross-platform conversion for research applications.
Owner:OTHAIR PROTHENA LTD +3
Composition for preventing, ameliorating, or treating cognitive dysfunction and alzheimer's disease comprising lactobacillus fermentum SRK414 strain
The present invention relates to a composition for preventing, ameliorating or treating cognitive dysfunction or Alzheimer's disease comprising, as an active ingredient, Lactobacillus fermentum SRK414 strain which has accession number KCTC13687BP. The strain of the present invention is excellent in reducing barrier permeability and reducing amyloid beta and tau proteins and has an excellent effect in improving cognitive function, and accordingly, the strain can be useful for a food and therapeutic agent for same purposes.
Owner:CHONGKUNDANG BIO
ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND THEIR USES
The invention is directed to a short-term induction treatment with anti-N3pGlu Aβ antibodies of a disease characterized by Aβ deposition in the brain, including Alzheimer's disease (AD), Down syndrome, and cerebral amyloid angiopathy (CAA). In some embodiments, patients are administered an induction dose of 10 to 60 mg / kg of an anti-N3pGlu Aβ antibody for a period of 6 months or less.
Owner:ELI LILLY & CO
Anti-amyloid beta antibodies and methods of use
PCT designated stageWO2026060081A1Nervous disorderImmunoglobulins against animals/humansAntiendomysial antibodiesAmyloid beta
Described are engineered antibodies that specifically bind amyloid beta (Aβ), nucleic acids encoding the anti-Aβ antibodies and methods of manufacturing the anti-Aβ antibodies. The anti-Aβ antibodies can be used to diagnose or treat neurodegenerative diseases or conditions associated with Aβ protein aggregation.
Owner:DENALI THERAPEUTICS INC
Test strip and method for detecting amyloid beta in urine
A test strip for detecting Aβ in urine includes a polyvinyl chloride (PVC) bottom plate. The PVC bottom plate is laid with a sample pad, a conjugation pad, a chromatography pad, and an absorbent pad that are overlapped in sequence. The conjugation pad is coated with colloidal gold particles conjugated to a monoclonal antibody. The chromatography pad is provided with a test line on the side proximate to the conjugation pad, and is provided with a control line on the side proximate to the absorbent pad. The test line is coated with an Aβ-binding polymer. The control line is coated with a goat anti-mouse IgG polyclonal antibody. The method is suitable for the following: routine clinical pathological examination; general screening of a large number of people and self-screening of home end-users; assisting the early diagnosis and prejudgment of mild cognitive impairment (MCI) clinically.
Owner:HUNAN QIANKANG TECH CO LTD
Spectroscopic analysis substrate for diagnosing dementia including hydrophilized graphene layer and spectroscopic device including same
The present application provides: a spectroscopic analysis substrate for diagnosing dementia, comprising a hydrophilized graphene layer; and a spectroscopic device comprising same. More specifically, the present application provides: a spectroscopic analysis substrate for diagnosing dementia, having improved accuracy due to increased binding force and selectivity for amyloid beta, the substrate comprising a hydrophilized graphene layer; and a spectroscopic device comprising the spectroscopic analysis substrate.
Owner:KUK IL GRAPHENE CO LTD +1
Methods for quantification of amyloid β peptides in plasma by mass spectrometry
The present invention relates to a method for preparing a plasma sample comprising amyloid beta peptides for analysis by mass spectrometry, comprising the steps of:a) contacting said plasma sample with a denaturing agent, b) performing a first solid phase extraction step on the solution obtained in step a) to recover a first eluate, c) performing a second solid phase extraction step on said first eluate obtained in step b) to recover a second eluate, and d) drying said second eluate obtained in step c) and processing it for analysis by mass spectrometry, wherein the solution obtained in step d) comprises intact amyloid beta peptides Aβ40 and Aβ42.
Owner:ARACLON BIOTECH
Relative undersupply of an amyloid beta aggregation inhibitor for improved detoxifying effects
Provided herein a method for treating or preventing a protein misfolding and deposition disease in a subject, by administering to the subject a low dose amount of compound (1). Provided herein is also a method for reversing or preventing the toxic effect of the misfolded and aggregated protein amyloid beta, by using compound (1) in a relative undersupply (reversed stoichiometric ratio) to achieve stronger detoxifying effects. Also provided dosages and administration thereof.
Owner:GALIMEDIX THERAPEUTICS INC